Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HPV (human papilloma virus) test predicts progress of cervical cancer:

This article was originally published in Clinica

Executive Summary

Testing for human papilloma virus (HPV) could predict the progression rate of cervical cancer, according to a study published in the Journal of the National Cancer Institute (September 3). Until now there have been no risk markers able to indicate if, and how fast, abnormal cells will progress to cancerous form. An international group of researchers used PCR to screen 2,404 women in Brazil for HPV over an eight-year period. They found that the presence of HPV speeded up the deterioration of abnormal cells by an average of 21 months. They said HPV testing could also cut hospital costs by reducing the need for invasive tests in low-risk women.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063456

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel